文章核心观点 - 公司Pyxis Oncology, Inc.可能存在违反受信义务的行为 [1] - 公司正面临调查,投资者可以联系律师事务所了解更多信息 [1] 公司信息 - Pyxis Oncology, Inc.是一家上市公司,股票代码为NASDAQ:PYXS [1] - 律师事务所Levi & Korsinsky在调查公司的相关情况 [1] - Levi & Korsinsky是一家全国性的律师事务所,在纽约、康涅狄格、加利福尼亚和华盛顿特区都有办事处 [2] - 该律师事务所的律师在证券诉讼方面有丰富的专业经验,代表全国各地的投资者,并成功追回了数亿美元的损失 [2]

RapidEye/iStock via Getty Images Pyxis Oncology (NASDAQ:PYXS) is an antibody and antibody-drug conjugate (ADC) developer that I covered back in March. At that time, I rated it a hold, as the company had the funds it needed to run its trials, but there was no near-term clinical catalyst. This article looks at updates from the company and the near-term catalyst of PYX-201 data. The clinical timeline While I lamented slippage to the timeline of clinical readouts in my previous article on PYXS, the timeline for ...

BOSTON, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in fireside chats and members of management will participate in one-on-one meetings at the following two upcoming investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY, on Septem ...

临床试验进展 - 公司正在开发针对难治性肿瘤的下一代治疗方案，包括抗体-药物偶联物(ADC)和免疫肿瘤学(IO)产品候选药物[84] - 公司的ADC产品候选药物PYX-201针对肿瘤基质中的EDB+FN进行靶向,在多种实体瘤动物模型中显示出良好的抗肿瘤活性[85] - PYX-201已于2022年12月获得FDA的IND批准,并于2023年第一季度开始了I期临床试验,目前已有72例受试者接受给药[85] - 公司的IO产品候选药物PYX-106是一种针对Siglec-15的全人源IgG1单克隆抗体,于2022年12月获得FDA的IND批准,并于2023年第二季度开始I期临床试验,目前已有33例受试者接受给药[86,87] - 公司于2023年8月完成收购Apexigen,新增了一款CD40激动剂PYX-107,该产品在多项临床试验中显示出良好的抗肿瘤活性和耐受性[87] 财务状况 - 公司自成立以来一直专注于研发活动,尚未有任何产品获批上市,报告了2024年上半年2060万美元和2023年上半年3510万美元的净亏损[87] - 截至2024年6月30日,公司累计亏损3.068亿美元,净权益1.698亿美元,现金及现金等价物1.557�美元[87] - 公司预计未来将大幅增加开支,主要用于推进PYX-201和PYX-106的临床试验[112] - 截至2024年6月30日,公司累计亏损3.068亿美元[112] - 2024年上半年,公司经营活动产生的现金流出为2,371.7万美元[114,115] - 2024年上半年,公司投资活动产生的现金流出为1,849.4万美元[114,116] - 2024年上半年,公司筹资活动产生的现金流入为5,762.1万美元[114,116] - 公司预计现有现金、现金等价物和短期投资将可为其运营提供资金支持至2026年下半年[116] 收入与费用 - 公司一次性确认了8,146万美元的特许权使用费收入和8,000万美元的特许权使用费出售收入[104] - 公司一次性确认了475万美元的特许权使用费成本[105] - 公司研发费用总体增加260万美元，其中PYX-201项目研发费用增加4,052万美元[96][97] - PYX-106项目研发费用增加462万美元[96][97] - 公司管理费用总体下降145.7万美元[110] - 公司其他收益净额增加114.9万美元，主要由于利息收入和租金收入增加[111] - 公司研发人员相关费用(包括股份支付)下降465.7万美元[107][108] - 公司其他研发费用增加814万美元[107] 融资活动 - 2024年1月30日,公司通过ATM发行计划完成了360万股普通股的销售,平均价格为3美元每股,获得总收益1,080万美元[112] - 2024年2月29日,公司完成了私募配售,发行了884.9371万股普通股和161.1215万份预付款认股权证,获得总收益5,000万美元[112] - 2024年3月25日,公司与诺华达成和解协议,诺华同意支付800万美元收购公司对Beovu®未来销售的权利[112]

临床试验进展 - 公司已在PYX-201 I期临床试验中给72名受试者用药，正在进行剂量递增和安全性监测[8] - 公司在PYX-106 I期临床试验中已给33名受试者用药，正在进行剂量递增和安全性监测[11] - 公司预计将在2024年秋季公布PYX-201 I期临床试验的初步数据[9] - 公司预计将在2024年底公布PYX-106 I期临床试验的初步数据[12] 财务状况 - 公司截至2024年6月30日的现金、现金等价物和短期投资总额为1.572亿美元，预计可提供资金支持到2026年下半年[13] - 2024年第二季度研发费用为1390万美元，同比增加22.8%,主要由于正在进行的PYX-201和PYX-106 I期临床试验相关的费用增加[14] - 2024年第二季度管理费用为610万美元,同比下降9.0%,主要由于专业和咨询费用降低[15] - 2024年第二季度净亏损为1730万美元,每股亏损0.29美元[16][17] - 截至2024年8月14日,公司的已发行普通股股数为58,942,243股[18]

BOSTON, July 29, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, and members of management will participate in one-on-one meetings at the BTIG Virtual Biotechnology Conference being held August 5-6, 2024. About Pyxis Oncology, Inc. Pyxis Oncology, Inc. is a clinical stage company focused on defeatin ...

BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, reported today that Pyxis Oncology’s Compensation Committee of the Board of Directors granted restricted stock units with respect to an aggregate of 89,530 shares of Pyxis Oncology’s common stock and stock options to purchase an aggregate of 111,913 shares of Pyxis Oncology’s common stock to five newly hired employees ...

BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: "PYXS"), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Michael A. Metzger to its Board of Directors, effective June 10, 2024. Mr. Metzger has over 25 years of experience in the biopharmaceutical sector, currently serving as Chief Executive Officer and as a member of the Board of Directors of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) s ...

Pyxis Oncology, Inc. (PYXS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.54 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 77.78%. A quarter ago, it was expected that this company would post a loss of $0.49 per share when it actually produced a loss of $0.33, delivering a surprise of 32.65%. Over the last four quarters, the company has s ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40881 Pyxis Oncology, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 83-1160910 (State or other jurisdiction of (I.R.S. Employer incorporatio ...